Quel est le prix pour Ergomed plc (2EM)

Le prix pour Ergomed plc (2EM) est $13.05

Quelle est la capitalisation boursière pour Ergomed plc (2EM)

La capitalisation boursière pour Ergomed plc (2EM) est $695.07M

Ergomed plc (2EM) Dividendes

Ergomed plc, alongside its affiliated entities, offers a comprehensive range of clinical trial services, encompassing planning, oversight, and execution, in addition to providing essential drug safety and medical information support. The company maintains an expansive global footprint, conducting operations throughout the United Kingdom, continental Europe, the Middle East, Africa, North America, Asia, and Australia. Its business is organized into two core divisions: Clinical Research Services and Pharmacovigilance. Ergomed assists pharmaceutical, biotechnology, and generic drug manufacturers by managing clinical development programs, facilitating post-market approval strategies, and delivering robust pharmacovigilance solutions. Their expertise is concentrated in several therapeutic domains, including oncology, haematology, allergy, respiratory, and neurology/CNS, with a notable specialization in the development of orphan drugs. Furthermore, they extend support services to clinical trial sites. Established in 1997, the organization originally traded as Ergomed Clinical Research Limited before rebranding as Ergomed plc in June 2014. Its corporate headquarters are situated in Guildford, United Kingdom.

Année	Dividende (ajusté pour divisions d’actions)	Changez
Pas assez de données pour les dates fournies.

Année

Dividende (ajusté pour divisions d’actions)

Changez

Pas assez de données pour les dates fournies.

Année	Dividende	Changez
Pas assez de données pour les dates fournies.

Année

Dividende

Changez

Pas assez de données pour les dates fournies.

Entreprise	Nombre de paiements de dividendes	Pays
Vertex Pharmaceuticals Incorporated VRTX.US	0.00%	US
Argenx SE ARGX.US	0.00%	NL
CSL Limited CSL.AX	64.00%	AU
Moderna, Inc. MRNA.US	0.00%	US
Lonza Group AG LONN.SW	0.00%	CH

Entreprise

Nombre de paiements de dividendes

Pays